Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternatives. The FDA has ruled that ...

TrumpRx is set to launch soon. President Donald Trump has been pressuring drug companies to lower prices. Americans currently pay about three times more for prescription medicine than patients in ...

Novo Nordisk has announced the launch of its Wegovy pill in the U.S. following FDA approval last month, as well as a collaboration with hybrid weight-inclusive primary and metabolic care provider ...